Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,260 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Mori S, Izumi H, Araki M, Liu J, Tanaka Y, Kagawa Y, Sagae Y, Ma B, Isaka Y, Sasakura Y, Kumagai S, Sakae Y, Tanaka K, Shibata Y, Udagawa H, Matsumoto S, Yoh K, Okuno Y, Goto K, Kobayashi SS. Mori S, et al. Among authors: okuno y. Commun Biol. 2024 Apr 4;7(1):412. doi: 10.1038/s42003-024-06116-6. Commun Biol. 2024. PMID: 38575808 Free PMC article.
A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Nakaoku T, Kohno T, Araki M, Niho S, Chauhan R, Knowles PP, Tsuchihara K, Matsumoto S, Shimada Y, Mimaki S, Ishii G, Ichikawa H, Nagatoishi S, Tsumoto K, Okuno Y, Yoh K, McDonald NQ, Goto K. Nakaoku T, et al. Among authors: okuno y. Nat Commun. 2018 Feb 12;9(1):625. doi: 10.1038/s41467-018-02994-7. Nat Commun. 2018. PMID: 29434222 Free PMC article.
Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations.
Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K, Ono F, Araki M, Kanada R, Ma B, Hayashi Y, Mimaki S, Yoh K, Kobayashi SS, Kohno T, Okuno Y, Goto K, Tsuchihara K, Soejima K. Ikemura S, et al. Among authors: okuno y. Proc Natl Acad Sci U S A. 2019 May 14;116(20):10025-10030. doi: 10.1073/pnas.1819430116. Epub 2019 May 1. Proc Natl Acad Sci U S A. 2019. PMID: 31043566 Free PMC article.
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mizuta H, Okada K, Araki M, Adachi J, Takemoto A, Kutkowska J, Maruyama K, Yanagitani N, Oh-Hara T, Watanabe K, Tamai K, Friboulet L, Katayama K, Ma B, Sasakura Y, Sagae Y, Kukimoto-Niino M, Shirouzu M, Takagi S, Simizu S, Nishio M, Okuno Y, Fujita N, Katayama R. Mizuta H, et al. Among authors: okuno y. Nat Commun. 2021 Feb 24;12(1):1261. doi: 10.1038/s41467-021-21396-w. Nat Commun. 2021. PMID: 33627640 Free PMC article.
Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancer.
Seto K, Shimizu J, Masago K, Araki M, Katayama R, Sagae Y, Fujita S, Horio Y, Sasaki E, Kuroda H, Okubo K, Okuno Y, Hida T. Seto K, et al. Among authors: okuno y. Cancer Genet. 2022 Aug;266-267:1-6. doi: 10.1016/j.cancergen.2022.05.001. Epub 2022 May 11. Cancer Genet. 2022. PMID: 35598548
1,260 results